Kazia Therapeutics Welcomes James Levine as New Chief Financial Officer

On June 1, 2026, Kazia Therapeutics Limited, a clinical-stage oncology company, proudly announced the appointment of James Levine as its Chief Financial Officer (CFO). With a noteworthy career spanning over two decades in investment banking and financial leadership roles within publicly traded biotech firms, Levine's vast experience will play a crucial role in advancing Kazia's innovative oncology solutions.

Extensive Experience in Finance and Strategic Partnerships

Dr. John Friend, CEO of Kazia Therapeutics, expressed excitement about Levine's appointment, stating, "James has built an impressive career leading financial strategy, strategic transactions, and major pharmaceutical collaborations, following an extensive career in investment banking." His significant contributions are anticipated as Kazia pushes forward with its lead compound, paxalisib.

Before joining Kazia, Levine served as the CFO of Cardiff Oncology, focusing on developing a PLK1 inhibitor therapy targeting solid tumors. His previous roles include working as CFO at Cidara Therapeutics, where he successfully led financial structuring for major licensing and partnership deals worth over $1.3 billion in collaborations with Mundipharma and Janssen Pharmaceuticals. Additionally, he has significant experience in corporate leadership roles, having been CEO at Verenium Corporation and Sapphire Energy.

Levine's career also includes a lengthy tenure at Goldman Sachs, where he served as Managing Director. He provided strategic advice to pharmaceutical and biotech clients across the U.S. and Europe on financing, mergers, acquisitions, and high-profile transactions, including the merger between Glaxo Wellcome and SmithKline Beecham.

Focused on Building Long-Term Value

In his new role at Kazia, Levine aims to focus on maximizing the value of the company’s promising pipeline, including their lead asset, paxalisib. He shared his enthusiasm, saying, "I am very excited to be joining Kazia as the Company advances paxalisib across multiple indications and builds out a promising pipeline targeting novel mechanisms of treatment resistance."

As Kazia Therapeutics continues to progress its clinical trials and pursue long-term value for patients and shareholders, Levine's financial expertise is expected to be integral in navigating the complexities of the biotechnology industry.

The Kazia Pipeline and Future Outlook

Kazia Therapeutics is focused on discovering and developing new treatments for cancer and currently has paxalisib under investigation for various forms of cancer, including glioblastoma and advanced breast cancer, among others. This investigational compound, a PI3K/Akt/mTOR pathway inhibitor, has been central to Kazia's efforts to offer new treatment options in oncology.

With the accumulating data from its clinical trials, paxalisib has already garnered several critical designations from the FDA, highlighting its potential impact in treating malignancies lacking effective therapies. The turnaround in advancements and strategies expected with Levine at the financial helm signifies a period of notable expectations for Kazia as they navigate toward regulatory approvals and broaden their drug development horizons.

Conclusion

In summary, James Levine's vast background in finance and strategic leadership positions Kazia Therapeutics for a potentially transformative phase as they continue to innovate in oncology. His joining signals a commitment to amplifying Kazia's efforts in overcoming the challenges of cancer treatment, ultimately aiming to improve patient outcomes and shareholder value alike. Kazia Therapeutics remains steadfast in its mission to develop pioneering therapies that can adapt and respond to the needs of patients battling cancer.